Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection

Hepatology Research

Volumn 38, Issue 6, 2008, Pages 622-628

  Kanada, Aimi ^a   Takehara, Tetsuo ^a   Ohkawa, Kazuyoshi ^a   Kato, Michio ^b   Tatsumi, Tomohide ^a   Miyagi, Takuya ^a   Sakamori, Ryotaro ^a   Yamaguchi, Shinjiro ^a   Uemura, Akio ^a   Kohga, Keisuke ^a   Sasakawa, Akira ^a   Hikita, Hayato ^a   Kawamura, Kiyomi ^b   Kanto, Tatsuya ^a   Hiramatsu, Naoki ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Coinfection; Drug resistant hepatitis B virus; Entecavir; Hepatitis B virus; Human immunodeficiency virus; Lamivudine

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; EFAVIRENZ; ENTECAVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS DNA; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHEMOLUMINESCENCE; COMORBIDITY; DIZZINESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPANESE; MALE; NUCLEOTIDE SEQUENCE; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN;

EID: 43049117534     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00307.x     Document Type: Article

References (22)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
2. Konopnicki D, Mocroft A, de Wit S et al. EuroSIDA Group. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
3. Thio CL, Seaberg EC, Skolasky R Jr et al. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-6.
4. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
5. Benhamou Y, Katlama C, Lunel F et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125: 705-12.
6. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
7. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-6.
8. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
9. Ono-Nita SK, Kato N, Shiratori Y et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103: 1635-40.
10. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-55.
11. Delaney WE, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-41.
12. Chang TT, Gish RG, de Man R et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
13. Lai CL, Shouval D, Lok AS et al. BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
14. Sherman M, Yurdaydin C, Sollano J et al. AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
15. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-11.
16. Colonno RJ, Rose R, Pokornowski K et al. Assessment at three years shows barrier to resistance is maintained in entecavir-treated nucleoside-naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2007; 44: 229A (Abstract).
17. Kanada A, Takehara T, Ohkawa K et al. Type B fulminant hepatitis is closely associated with a highly mutated hepatitis B virus strain. Intervirology 2007; 50: 394-401.
18. McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir - Effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-21.
19. Benhamou Y, Thibault V, Vig P et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44: 62-7.
20. Benhamou Y, Fleury H, Trimoulet P et al. TECOVIR Study Group. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43: 548-55.
21. Suzuki F, Akuta N, Suzuki Y et al. Selection of a virus strain resistant to entecavir in a nucleoside-naïve patient with hepatitis B of genotype H. J Clin Virol 2007; 39: 149-52.
22. Ozasa A, Tanaka Y, Orito E et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326-34.